Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Hypereosinophilia and Hypereosinophilic Syndrome and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
Phase: PHASE2 → PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Bramstedt, Germany , Bern, Switzerland , Bethesda, United States , Bologna, Italy , Boston, United States , Cincinnati, United States , Denver, United States , Edmonton, Canada , Halifax, Canada , Hamilton, Canada and 19 more locations